Table 1. RNase H Inhibition of the Newly Synthesized Compounds 6a–h, 7a–h, 8a–c, 9a–c, 10a–i, and 11a–i.

cpd	IC50 (μM)a	cpd	IC50 (μM)a	cpd	IC50 (μM)a
6a	14.3 ± 2.35	7g	63 ± 7.0	10g	6.8 ± 0.4
6b	>100	7h	13.7 ± 1.3	10h	7.9 ± 0.7
6c	>100	8a	>100	10i	25.8 ± 3.7
6d	>100	8b	>100	11a	3.21 ± 0.94
6e	>100	8c	>100	11b	0.27 ± 0.05
6f	9.4 ± 0.2	9a	>100	11c	2.38 ± 0.59
6g	97 ± 5.0	9b	>100	11d	4.50 ± 0.60
6h	9.4 ± 0.7	9c	>100	11e	1.73 ± 0.31
7a	75 ± 4.5	10a	5.4 ± 1.2	11f	70 ± 8
7b	>100	10b	17.8 ± 1.2	11g	23 ± 3
7c	>100	10c	8.5 ± 1.6	11h	5.8 ± 1.4
7d	>100	10d	5.50 ± 0.93	11i	9.2 ± 0.4
7e	>100	10e	4.15 ± 0.55	1	10 ± 1.2
7f	25.3 ± 5.3	10f	8.1 ± 0.4

^aInhibitory concentration 50% (μM) determined from dose–response curves: experiments performed against HIV-1 RT-associated RNase H activity.

^bBn, benzyl.